325 related articles for article (PubMed ID: 12897980)
1. Bone mineral density and bone metabolism in Duchenne muscular dystrophy.
Bianchi ML; Mazzanti A; Galbiati E; Saraifoger S; Dubini A; Cornelio F; Morandi L
Osteoporos Int; 2003 Sep; 14(9):761-7. PubMed ID: 12897980
[TBL] [Abstract][Full Text] [Related]
2. Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy.
Tian C; Wong BL; Hornung L; Khoury JC; Miller L; Bange J; Rybalsky I; Rutter MM
Neuromuscul Disord; 2016 Nov; 26(11):760-767. PubMed ID: 27614576
[TBL] [Abstract][Full Text] [Related]
3. Low bone mineral density and decreased bone turnover in Duchenne muscular dystrophy.
Söderpalm AC; Magnusson P; Ahlander AC; Karlsson J; Kroksmark AK; Tulinius M; Swolin-Eide D
Neuromuscul Disord; 2007 Dec; 17(11-12):919-28. PubMed ID: 17627820
[TBL] [Abstract][Full Text] [Related]
4. Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy.
Tian C; Wong BL; Hornung L; Khoury JC; Rybalsky I; Shellenbarger KC; Rutter MM
Neuromuscul Disord; 2020 Jul; 30(7):599-610. PubMed ID: 32680651
[TBL] [Abstract][Full Text] [Related]
5. Regional changes in bone area and bone mineral content in boys with duchenne muscular dystrophy receiving corticosteroid therapy.
Crabtree NJ; Roper H; McMurchie H; Shaw NJ
J Pediatr; 2010 Mar; 156(3):450-5. PubMed ID: 19880140
[TBL] [Abstract][Full Text] [Related]
6. Different bone health progression patterns and early-stage risk marker in glucocorticoid-treated ambulatory Duchenne muscular dystrophy.
Zhou L; Zhou H; Xu H; Sun X; Chen X; Fan P; Cai X; Wang Q
Osteoporos Int; 2024 Jun; 35(6):997-1005. PubMed ID: 38277031
[TBL] [Abstract][Full Text] [Related]
7. Skeletal disproportion in glucocorticoid-treated boys with Duchenne muscular dystrophy.
Kao KT; Joseph S; Capaldi N; Brown S; Di Marco M; Dunne J; Horrocks I; Shepherd S; Ahmed SF; Wong SC
Eur J Pediatr; 2019 May; 178(5):633-640. PubMed ID: 30762116
[TBL] [Abstract][Full Text] [Related]
8. The time to and determinants of first fractures in boys with Duchenne muscular dystrophy.
Ma J; McMillan HJ; Karagüzel G; Goodin C; Wasson J; Matzinger MA; DesClouds P; Cram D; Page M; Konji VN; Lentle B; Ward LM
Osteoporos Int; 2017 Feb; 28(2):597-608. PubMed ID: 27774565
[TBL] [Abstract][Full Text] [Related]
9. Reduced bone mineral density in adolescents with Duchenne Muscular Dystrophy (DMD) and scoliosis.
Tsaknakis K; Jäckle K; Lüders KA; Lorenz HM; Braunschweig L; Hell AK
Osteoporos Int; 2022 Sep; 33(9):2011-2018. PubMed ID: 35583603
[TBL] [Abstract][Full Text] [Related]
10. Bone density and bone health alteration in boys with Duchenne Muscular Dystrophy: a prospective observational study.
Suthar R; Reddy BVC; Malviya M; Sirari T; Attri SV; Patial A; Tageja M; Didwal G; Khandelwal NK; Saini AG; Saini L; Sahu JK; Dayal D; Sankhyan N
J Pediatr Endocrinol Metab; 2021 May; 34(5):573-581. PubMed ID: 33838091
[TBL] [Abstract][Full Text] [Related]
11. Use of bone age for evaluating bone density in patients with Duchenne muscular dystrophy: A preliminary report.
Al-Zougbi A; Mathews KD; Shibli-Rahhal A
Muscle Nerve; 2019 Apr; 59(4):422-425. PubMed ID: 30636004
[TBL] [Abstract][Full Text] [Related]
12. Risk factors associated with prevalent vertebral fractures in Duchenne muscular dystrophy.
Phung K; McAdam L; Ma J; McMillan HJ; Jackowski S; Scharke M; Matzinger MA; Shenouda N; Koujok K; Jaremko JL; Smit K; Walker S; Hartigan C; Khan N; Konji VN; MacLeay L; Page M; Sykes E; Robinson ME; Alos N; Cummings EA; Ho J; Sbrocchi AM; Stein R; Saleh D; Craven BC; Dang UJ; Siminoski K; Rauch F; Ward LM
Osteoporos Int; 2023 Jan; 34(1):147-160. PubMed ID: 36342539
[TBL] [Abstract][Full Text] [Related]
13. Low bone density and bone metabolism alterations in Duchenne muscular dystrophy: response to calcium and vitamin D treatment.
Bianchi ML; Morandi L; Andreucci E; Vai S; Frasunkiewicz J; Cottafava R
Osteoporos Int; 2011 Feb; 22(2):529-39. PubMed ID: 20458570
[TBL] [Abstract][Full Text] [Related]
14. Bone density and alendronate effects in Duchenne muscular dystrophy patients.
Houston C; Mathews K; Shibli-Rahhal A
Muscle Nerve; 2014 Apr; 49(4):506-11. PubMed ID: 23835890
[TBL] [Abstract][Full Text] [Related]
15. Skeletal health in Duchenne dystrophy: bone-size and subcranial dual-energy X-ray absorptiometry analyses.
King WM; Kissel JT; Visy D; Goel PK; Matkovic V
Muscle Nerve; 2014 Apr; 49(4):512-9. PubMed ID: 23893858
[TBL] [Abstract][Full Text] [Related]
16. Intermittent PTH treatment improves bone and muscle in glucocorticoid treated Mdx mice: A model of Duchenne Muscular Dystrophy.
Yoon SH; Grynpas M; Mitchell J
Bone; 2019 Apr; 121():232-242. PubMed ID: 30716510
[TBL] [Abstract][Full Text] [Related]
17. Histomorphometry and Bone Matrix Mineralization Before and After Bisphosphonate Treatment in Boys With Duchenne Muscular Dystrophy: A Paired Transiliac Biopsy Study.
Misof BM; Roschger P; McMillan HJ; Ma J; Klaushofer K; Rauch F; Ward LM
J Bone Miner Res; 2016 May; 31(5):1060-9. PubMed ID: 26615086
[TBL] [Abstract][Full Text] [Related]
18. Effect of 25-HydroxyVitamin D Deficiency and Its Interaction with Prednisone Treatment on Musculoskeletal Health in Growing Mdx Mice.
Yoon SH; Sugamori KS; Grynpas MD; Mitchell J
Calcif Tissue Int; 2018 Sep; 103(3):311-323. PubMed ID: 29691609
[TBL] [Abstract][Full Text] [Related]
19. Growth, bone health & ambulatory status of boys with DMD treated with daily vs. intermittent oral glucocorticoid regimen.
Crabtree NJ; Adams JE; Padidela R; Shaw NJ; Högler W; Roper H; Hughes I; Daniel A; Mughal MZ
Bone; 2018 Nov; 116():181-186. PubMed ID: 30055340
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Neridronate in the Management of Bone Loss in Patients with Duchenne Muscular Dystrophy: Results from a Pilot Study.
Moretti A; Liguori S; Paoletta M; Gimigliano F; Iolascon G
Adv Ther; 2022 Jul; 39(7):3308-3315. PubMed ID: 35614293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
